When editing bacteria with CRISPR, less is more
Research team develops approach that increases efficiency of genome editing
Systematically attenuating DNA targeting activity can achieve CRISPR-driven editing in bacteria, greatly boosting colony counts and even increasing the frequency of precise genome editing. This was shown in a study of the Helmholtz Institute Würzburg (HIRI) in collaboration with the Helmholtz Centre for Infection Research (HZI) in Braunschweig. The findings were published in the journal Nature Communications.
Symbolic image
Computer-generated image
The ability to genetically manipulate bacteria has been key to exploring the microbial world. Genome editing is crucial for the development of new antibiotics and harnessing bacteria as miniature factories for the sustainable production of chemicals, materials, and therapeutics. Tools based on CRISPR “gene scissors” have proven instrumental in this regard, making it fast, easy, and reliable to create edits in different bacteria.
The general technology requires a CRISPR ribonucleic acid (crRNA) serving as a "guide RNA". It helps detect certain regions of a genome for targeted DNA cleavage. Proteins involved in homologous recombination—a natural process of exchanging genetic material between chromosomes—weave in designed “repair template” DNA afterwards to create an edited sequence of the strand.
Breaking the stumbling block
In a current study, which was published in the journal Nature Communications, researchers from the Würzburg Helmholtz Institute for RNA-based Infection Research (HIRI) in collaboration with the Helmholtz Centre for Infection Research (HZI) in Braunschweig address a central challenge to genome editing in bacteria.
“CRISPR-based genome editing has become a common molecular technology, but there is a notable stumbling block,” says HIRI department head Chase Beisel, who led the study. “During exponential growth, bacteria initiate genome replication multiple times in one cell cycle to keep pace with cell division. By efficiently cutting DNA, CRISPR leads to the untimely death of the cell. Consequently, editing requires efficient recombination and high transformation efficiencies, which are unavailable in most bacterial strains, including those relevant to human disease and industrial biotechnology,” Beisel explains.
A seemingly paradoxical concept
Daphne Collias, postdoc in Beisel’s lab at the Helmholtz Institute Würzburg, is the first author of the study. Describing the background to the findings she says: “We found that attenuating the cutting activity of CRISPR would allow the cell to repair the cut DNA using the provided template for homologous recombination. As a result, we could drive homologous recombination and get many more surviving cells.”
The researchers also developed a suite of approaches that could pull back activity, including using different formats for the guide RNA that directs cutting by the Cas9 protein, using versions of Cas9 that cut less efficiently, reducing guide RNA expression, introducing interfering structures onto the guide RNA, and mutating the sequence in the guide RNA used to find its DNA target.
“We called the modified guide RNAs ‘attenuated guide RNAs’ or atgRNAs, representing a flexible means of achieving CRISPR-driven editing,” Collias reports. “Not every approach could drive editing, although we usually could find at least one for each editing setup.”
Future impact
As a proof-of-principle, the Beisel lab teamed up with HZI department head Till Strowig and his lab to enhance editing in different strains of Klebsiella bacteria. Using a multidrug resistant strain, they leveraged editing to reverse resistance against the antibiotic ampicillin.
The new editing approach can advance basic research on bacteria involved in human health. Edited bacteria could also be used as therapeutic probiotics or as production hosts for therapeutics in the future.
Original publication
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
